-
Mashup Score: 0Pulmonary Hypertension Risk in PV: How Does Its Presence Impact Patient Survival? | Docwire News - 14 hour(s) ago
Thrombosis history was not predictive of overall survival in patients with pulmonary hypertension risk and PV, a study found.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Investigational BTK Inhibitor Rilzabrutinib Receives FDA Orphan Drug Designation For 2 Rare Diseases | Docwire News - 1 day(s) ago
The FDA has granted orphan drug designation to rilzabrutinib for the treatment of warm autoimmune hemolytic anemia and and IgG4-related disease.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
In regulatory news on #Heme Today, @US_FDA has granted Orphan Drug Designation to #rilzabrutinib from @sanofi for tx of both #warmautoimmunehemolyticanemia and #IgG4-related disease. https://t.co/XhFPuDtJL8
-
-
Mashup Score: 0Reduced-Dose Apixaban Anticoagulation Noninferior to Full Dose in Cancer-Associated VTE Prevention | Docwire News - 2 day(s) ago
The reduced-dose oral regimen also had lower incidence of clinically relevant bleeding complications and mortality rate.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
A randomized clinical trial of oral #apixaban to prevent cancer-associated #venousthromboembolism found that an extended, reduced-dose regimen of the anticoagulant had reduced clinically relevant bleeding, mortality vs the full-dose regimen. #Heme, #VTE https://t.co/NgBHYFX0Qg
-
-
Mashup Score: 0Reduced-Dose Apixaban Anticoagulation Noninferior to Full Dose in Cancer-Associated VTE Prevention | Docwire News - 2 day(s) ago
The reduced-dose oral regimen also had lower incidence of clinically relevant bleeding complications and mortality rate.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
A randomized clinical trial of oral #apixaban to prevent cancer-associated #venousthromboembolism found that an extended, reduced-dose regimen of the anticoagulant had reduced clinically relevant bleeding, mortality vs the full-dose regimen. #Heme, #VTE https://t.co/NgBHYFX0Qg
-
-
Mashup Score: 3Novel Cell Therapy Product for Bone Marrow Failure Syndromes Receives FDA Aplastic Anemia Orphan Dru | Docwire News - 3 day(s) ago
In a phase 1 trial the product performed favorably in aplastic anemia, myelofibrosis, and hypoplastic myelodysplasia.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
On #Heme Today: @US_FDA grants #aplasticanemia ODD to a novel cell therapy product which showed promising phase 1 results also in #myelofibrosis, #hypoplasticmyelodysplasia https://t.co/GOh3Lwf8H5
-
-
Mashup Score: 2Pushing the Limits for More Treatment Options for Von Willebrand Disease | Docwire News - 4 day(s) ago
New preclinical developments are pushing the limits for more treatment options for von Willebrand disease, the most common bleeding disorder.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
#Heme Today is bringing you a research news update on noteworthy #vonWillebranddisease tx agents in development. #HMB002, #VGA039, #VWD https://t.co/FVJjnkAM4Z
-
-
Mashup Score: 0Investigational T-Cell Immunotherapy Superior to Standard HSCT in Rate of Survival Plus GvHD Freedom | Docwire News - 6 day(s) ago
A phase 3 study comparing the treatments in multiple hematologic malignancies also saw greater overall survival at one year.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
In the #PrecisionT study, a new allogeneic T-cell immunotherapy from @OrcaBio produced survival-without-#GVHD favorable over conventional HSCT in hematologic malignancy tx. #acutelymphoblasticleukemia, #AML, #MDS, #graftversushostdisease, #Heme https://t.co/GmoXtBDC55
-
-
Mashup Score: 0FDA Grants Orphan Drug Designation to Bexobrutideg for Waldenström Macroglobulinemia | Docwire News - 7 day(s) ago
Bexobrutideg, an orally bioavailable, brain-penetrant BTK degrader, is being evaluated in a dose-escalation (phase 1a) and cohort-expansion (phase 1b) study.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
On #Heme Today: #Bexobrutideg from @Nurix_Tx has received Orphan Drug Designation from @US_FDA for tx of #Waldenstrommacroglobulinemia. #NX5948 https://t.co/lOeSGx2642
-
-
Mashup Score: 0Reduced-Dose Apixaban Anticoagulation Noninferior to Full Dose in Cancer-Associated VTE Prevention | Docwire News - 7 day(s) ago
The reduced-dose oral regimen also had lower incidence of clinically relevant bleeding complications and mortality rate.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
A randomized clinical trial of oral #apixaban to prevent cancer-associated #venousthromboembolism found that an extended, reduced-dose regimen of the anticoagulant had reduced clinically relevant bleeding, mortality vs the full-dose regimen. #Heme, #VTE https://t.co/NgBHYFX0Qg
-
-
Mashup Score: 1FDA Grants Orphan Drug Designation for MDS to Investigational CLEVER-1-Targeting Immunotherapy | Docwire News - 8 day(s) ago
The agent recalibrates the immune system to attack tumors and increases cancer susceptibility to standard of care therapy.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
ICYMI on #Heme Today in new @US_FDA Orphan Drug Designations: The novel humanized antibody #bexmarilimab from @FaronPharm now has ODD for #myelodysplasticsyndromes as well as for #acutemyeloidleukemia. #MDS, #AML, #BEXMAB, #azacitidine https://t.co/HRB0BN5MqE
-
In a study, researchers from @WeillCornell examined #pulmonaryhypertension risk in pts with #polycythemiavera and possible associations with survival outcomes. How useful is thrombosis hx for prognosis in this population? https://t.co/EA5iktCQtv